Overview

A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse events throughout the study period.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:

- Patients with open angle glaucoma and/or ocular hypertension requiring a reduction of
IOP who were insufficiently responsive to topical betablockers

Exclusion Criteria:

- Previous and current treatment with any topical ophthalmic drug containing
prostaglandins; any condition in which treatment with the betablocking agent, timolol,
was contraindicated.